Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Laiyang Jiangbo Pharma to Execute Reverse Merger

publication date: Oct 3, 2007
Laiyang Jiangbo Pharmaceuticals of Shandong will effect a reverse merger with Genesis Technology Group, which is listed on the OTC Bulletin Board. In its fiscal 2007, Laiyang Jiangbo earned $22 million on $76 million of revenue. It has assets of $55 million, including cash totaling $17 million. The owners of the parent of Laiyang Jiangbo Pharma will be issued stock equivalent to 75% of the new Genesis Technology, making the transaction worth $81 million to them. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital